Mass Spectrometry

Biography

Gary w. Caldwell is a working in johnson & johnson, usa. His recharge skills on chromatography ,mass spectrometry,liquid chromatography, sample preparation,analytical chemistry instrumentation spectrometrychromatographic method development.

 

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the synovial lining of the joints. It affects females more frequently than males and is typically diagnosed between the ages of 40-60 years with symptoms developing gradually.  If untreated, RA can lead to permanent joint damage and an increased risk of premature mortality. Synthetic DMARDS (sDMARDs) such as methotrexate (MTX), and biological DMARDS (bDMARDs) such as TNF-α antagonists (e.g., Etanercept, Adalimumab, or Infliximab), and antibodies that deplete B cells (e.g., Rituximab) are widely used in inhibiting synovial inflammation, and retarding bone erosion. It has been estimated that 30-40% of patients have poor or no response to these treatments. Metabolomics is a rapidly developing approach in biomarker research which involves the measurement of the set of final products and by products of metabolic pathways using NMR and mass spectrometry methods. Since RA disrupts metabolite (products) pathological processes, metabolomics can measure the alterations in these metabolite profiles long before overt signs and symptoms of the disease appears. Metabolomics should provide a more accurate representation of the RA phenotype than that accounted for by genetic, epigenetic, gastrointestinal microbiome and environmental factors. Many metabolomics studies have been published identifying potential RA biomarkers for use in diagnosis, prognosis or prediction of drug treatment. Here we discuss the advantages and disadvantages of metabolomics RA biomarker research using mass spectrometry techniques.